Accelerators of Osteogenesis by Recombinant Human Bone Morphogenetic Protein-2

Bone morphogenetic protein (BMP) appears to be one of the most promising cytokine and for clinical use in reconstructive surgery for bony defects and augmentation. To evaluate the effect of basic fibroblast growth factor (bFGF), FK506, elcatonin, and hyperbaric oxygenation (HBO) on osteoinduction by...

Full description

Saved in:
Bibliographic Details
Main Authors: Yasunori Okubo (Author), Kenji Kusumoto (Author), Kazuhisa Bessho (Author)
Format: Book
Published: AboutScience Srl, 2007-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c18d6392e364482a9f6cd443204df002
042 |a dc 
100 1 0 |a Yasunori Okubo  |e author 
700 1 0 |a Kenji Kusumoto  |e author 
700 1 0 |a Kazuhisa Bessho  |e author 
245 0 0 |a Accelerators of Osteogenesis by Recombinant Human Bone Morphogenetic Protein-2 
260 |b AboutScience Srl,   |c 2007-01-01T00:00:00Z. 
500 |a 1177-3928 
520 |a Bone morphogenetic protein (BMP) appears to be one of the most promising cytokine and for clinical use in reconstructive surgery for bony defects and augmentation. To evaluate the effect of basic fibroblast growth factor (bFGF), FK506, elcatonin, and hyperbaric oxygenation (HBO) on osteoinduction by recombinant human bone morphogenetic protein-2 (rhBMP-2), 2 or 5 μg of rhBMP-2 was implanted into intramuscular sites of rats. At 21 days after implantation, the osteoinductive activity in the treatment group and control group was compared radiographically, biochemically, and histologically. The amount of new bone in the treatment group was signifi cantly greater than that in the control group. The alkaline phosphatase activity and calcium content in the treatment group were signifi cantly higher than those in the control group. These results suggest that bFGF, FK506, elcatonin, and HBO accelerated the activity and rate of osteoinduction by rhBMP2. These results may be useful when BMP is applied clinically in near future. 
546 |a EN 
690 |a FK506 
690 |a Basic fibroblast growth factor (bFGF) 
690 |a elcatonin 
690 |a hyperbaric oxygenation (HBO) 
690 |a Recombinant human bone morphogenetic protein 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Target Insights, Vol 2, Pp 55-60 (2007) 
787 0 |n http://la-press.com/article.php?article_id=88 
787 0 |n https://doaj.org/toc/1177-3928 
856 4 1 |u https://doaj.org/article/c18d6392e364482a9f6cd443204df002  |z Connect to this object online.